CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of registered nurses, nurse practitioners and clinical nurse specialists involved in the treatment of follicular lymphoma (FL).
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with FL.
  
  LEARNING OBJECTIVES

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), and use this information to enhance decision-making for patients.
  • Evaluate published research data and consider the clinical and biologic factors in the selection of an induction approach for patients with newly diagnosed FL requiring active therapy.
  • Appraise the rationale for and available data documenting the utility of lenalidomide in combination with rituximab for newly diagnosed and R/R FL, and use this information to counsel patients regarding what role, if any, this regimen should play in their care.
  • Recognize the relevance of prior therapeutic exposure and other patient and disease characteristics to the selection and sequencing of available systemic treatments for patients with R/R FL.
  • Educate patients about the side effects associated with approved therapies commonly used in the management of FL, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Describe available and emerging data with other investigational agents and strategies currently under evaluation for FL, and where applicable, refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENTS
  Audio Program: This educational activity for 1.75 contact hours is provided by RTP during the period of December 2020 through December 2021.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1.25 contact hours is provided by RTP during the period of December 2020 through December 2021.
  
  This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/FLNurses20/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/FLNurses20/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/FLNurses20/Video.
  
  Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/FLNurses20/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/FLNurses20.
  
  CONTENT VALIDATION AND DISCLOSURES
  RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Robin Klebig, APRN, CNP, AOCNP
  Nurse Practitioner
  Assistant Professor of Medicine
  Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  No financial interests or affiliations to disclose.
  
  Ann S LaCasce, MD, MMSc
  Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
  Associate Professor of Medicine, Harvard Medical School
  Lymphoma Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Bristol-Myers Squibb Company.
  
  Release date: December 2020
  Expiration date: December 2021
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.